These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38097064)

  • 1. Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis.
    Tanaka M; Kaji K; Nishimura N; Asada S; Koizumi A; Matsuda T; Yorioka N; Tsuji Y; Fujinaga Y; Sato S; Namisaki T; Akahane T; Yoshiji H
    Biochim Biophys Acta Mol Cell Res; 2024 Feb; 1871(2):119649. PubMed ID: 38097064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.
    Cabrera D; Ruiz A; Cabello-Verrugio C; Brandan E; Estrada L; Pizarro M; Solis N; Torres J; Barrera F; Arrese M
    Dig Dis Sci; 2016 Nov; 61(11):3190-3198. PubMed ID: 27572941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats.
    Takeda S; Kaji K; Nishimura N; Enomoto M; Fujimoto Y; Murata K; Takaya H; Kawaratani H; Moriya K; Namisaki T; Akahane T; Yoshiji H
    Mol Nutr Food Res; 2021 Dec; 65(24):e2100526. PubMed ID: 34687151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.
    Burks TN; Andres-Mateos E; Marx R; Mejias R; Van Erp C; Simmers JL; Walston JD; Ward CW; Cohn RD
    Sci Transl Med; 2011 May; 3(82):82ra37. PubMed ID: 21562229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice.
    Iwai S; Kaji K; Nishimura N; Kubo T; Tomooka F; Shibamoto A; Suzuki J; Tsuji Y; Fujinaga Y; Kitagawa K; Namisaki T; Akahane T; Yoshiji H
    Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166770. PubMed ID: 37276988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
    Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
    Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.
    Yoshida T; Tabony AM; Galvez S; Mitch WE; Higashi Y; Sukhanov S; Delafontaine P
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2322-32. PubMed ID: 23769949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
    Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
    J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnoliae Cortex Alleviates Muscle Wasting by Modulating M2 Macrophages in a Cisplatin-Induced Sarcopenia Mouse Model.
    Hong M; Han IH; Choi I; Cha N; Kim W; Kim SK; Bae H
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF-α in senescence-accelerated mice.
    Shirakami Y; Kato J; Maeda T; Ideta T; Imai K; Sakai H; Shiraki M; Shimizu M
    J Gastroenterol Hepatol; 2023 May; 38(5):800-808. PubMed ID: 36890117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas.
    Morales MG; Abrigo J; Acuña MJ; Santos RA; Bader M; Brandan E; Simon F; Olguin H; Cabrera D; Cabello-Verrugio C
    Dis Model Mech; 2016 Apr; 9(4):441-9. PubMed ID: 26851244
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Yang L; Jiang X; Fu S; Tan J; Dian W; Zhou Y
    Discov Med; 2024 Feb; 36(181):402-414. PubMed ID: 38409845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression.
    Yoshida T; Semprun-Prieto L; Sukhanov S; Delafontaine P
    Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1565-70. PubMed ID: 20228261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia.
    Kingsley J; Torimoto K; Hashimoto T; Eguchi S
    Clin Sci (Lond); 2021 Nov; 135(21):2503-2520. PubMed ID: 34751393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions.
    Warner Ii ER; Satapathy SK
    J Clin Exp Hepatol; 2023; 13(1):162-177. PubMed ID: 36647414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice.
    Liu CW; Huang CC; Hsu CF; Li TH; Tsai YL; Lin MW; Tsai HC; Huang SF; Yang YY; Hsieh YC; Lee TY; Tsai CY; Huang YH; Hou MC; Lin HC
    BMJ Open Gastroenterol; 2020 May; 7(1):. PubMed ID: 32371503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy.
    Yoshida T; Delafontaine P
    Cells; 2020 Aug; 9(9):. PubMed ID: 32858949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous insulin-like growth factor 1 attenuates cisplatin-induced muscle atrophy in mice.
    Sakai H; Asami M; Naito H; Kitora S; Suzuki Y; Miyauchi Y; Tachinooka R; Yoshida S; Kon R; Ikarashi N; Chiba Y; Kamei J
    J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1570-1581. PubMed ID: 34268902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.